M. GLENN KOENIG, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The need for a trivalent botulinus antitoxin containing antitoxins A, B, and E has long been recognized (1, 2). Thus, the licensure of such a preparation and its availability from the National Communicable Disease Center in Atlanta is welcome news (3). Formerly, only bivalent A, B antitoxin was licensed in this country despite the increased incidence of type E disease since 1960; furthermore, from 1960 through 1967 type E botulism has had a death-to-case ratio over twice that reported for type A and four times that reported for type B disease (3). It is true that most instances of type
KOENIG MG. Trivalent Botulinus Antitoxin. Ann Intern Med. 1969;70:643–645. doi: https://doi.org/10.7326/0003-4819-70-3-643
Download citation file:
Published: Ann Intern Med. 1969;70(3):643-645.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use